1697-P: Further Real-World Outcomes Using Medication and Intensive Lifestyle Intervention to Treat Obesity and Improve Diabetes at Scale

Introduction: More than 2/3 adults in the US have overweight or obesity. Increasing obesity rates profoundly impact diabetes and cardiometabolic disease. We established a digital metabolic health company to provide medically-supervised obesity treatment at scale. Methods: The program used the combination of GLP-1 medication, medical supervision, and a proprietary lifestyle intervention. Patients who reached at least 12 months (mo) in the core program and a smaller subset who reached 24 mo were analyzed for weight change, metabolic labs (baseline and 12mo) and patient-completed questionnaires (baseline, 6, and 12mo) using data where available in this real-world setting. Results: The cohort who reached at least 12mo included 6,167 patients. For members with HbA1c at both baseline and 12mo (n=2,568), there were 3.4% and 23.7% who met baseline A1c criteria for diabetes and prediabetes. Average weight loss at 12 and 24 months was 16.39% (n=5,341) and 16.02% (n=169). Average weight loss for patients with diabetes or prediabetes at 12, 15 and 18 mo was 15.6% (n=1,375), 16.6% (n=782), and 16.7% (n=385). Patients with diabetes and prediabetes saw average improvements for HbA1c of -1.5 and -0.47 percentage points, respectively. 78.2% of patients with HbA1c levels 5.7% at baseline were 5.7% at 12 months. Across the cohort, fasting plasma insulin levels decreased in 71.3% (n=1,978). Positive changes were also seen for other metabolic markers and patient-reported outcomes. Conclusion: Patients in a digital metabolic health program achieved robust and sustained weight loss through 24 months. For those with diabetes or prediabetes, 84.2% achieved categorical improvement to diabetes status. Significant weight loss, reduction in HbA1c and insulin, improvements to other metabolic markers, and positive changes to health behaviors were also seen. These results offer promise in addressing the obesity epidemic and reversing its adverse impact on diabetes. Disclosure K. Boyd: Consultant; Calibrate. Employee; Caire, WndrHLTH. K.L. Medeiros: None. I. Kenyon: Employee; Calibrate Health Inc. D.H. Ryan: Advisory Panel; Altimmune Inc., Amgen Inc., Biohaven, Calibrate, Carmot Therapeutics, Inc., CinRx. Other Relationship; Epitomee. Advisory Panel; Gila Therapeutics. Other Relationship; Eli Lilly and Company, Novo Nordisk, Scientific Intake. Advisory Panel; Structure Therapeutics, Inc., Wondr Health. Other Relationship; Xeno. Advisory Panel; Zealand Pharma A/S.